Press Releases

When Dr. Roswell Park established the first center in the United States dedicated solely to the study of cancer, he enlisted some of the best and brightest minds from across the globe. Today, Roswell Park Comprehensive Cancer Center continues to be a world-class destination for scientists and oncologists — not only as a career home, but as a place to learn about cancer science and clinical practice. Through two new collaborative summer programs, the cancer center is now expanding its engagement with young learners.

Two local organizations dedicated to serving others — the Seneca-Babcock Community Association and Buffalo Adult & Teen Challenge — have expanded their programming and culinary offerings following two major projects supported by a grant from the CARES Program at Roswell Park Comprehensive Cancer Center.

National research and information resource Castle Connolly has named 37 Roswell Park Comprehensive Cancer Center physicians to its 2022 Top Doctors List. These experts are nominated through surveys completed by fellow physicians across the country.

Following a national search, Roswell Park Comprehensive Cancer Center has appointed Marco Davila, MD, PhD, as Senior Vice President and Associate Director for Translational Research and Vice Chair for Cellular Therapies.

An accomplished research leader with a record of important discoveries in cancer biology and precision therapeutics, Roswell Park Comprehensive Cancer Center’s Erik Knudsen, PhD, has been promoted to Associate Director of Basic Science Research.

To improve career pathways for students in the health sciences, Roswell Park Comprehensive Cancer Center and Trocaire College have partnered to launch the Roswell Scholars program.

A brain cancer vaccine developed at Roswell Park Comprehensive Cancer Center — SurVaxM — is being utilized in a pilot study in children and adolescents marking the first clinical trial of the immunotherapy in a pediatric population. The multicenter trial is sponsored by the Pediatric Brain Tumor Consortium

On June 7, in a talk at the ASCO Annual Meeting 2022, Eunice Wang, MD, will present the long-term results of a phase 2 clinical trial combining crenolanib with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML).

Roswell Park Professor of Neurosurgery Michael Ciesielski, PhD, is presenting the most recent findings from the completed phase 2A study of the immunotherapy SurVaxM at a poster session tomorrow, June 5, at the American Society of Clinical Oncology (ASCO) 2022 annual meeting. The largest clinical cancer meeting in the world, the conference continues through June 7 in Chicago.